Joint Statement: health organisations define EHDS’ opt-out required for life-saving research
- Photo Info
- Download
One document
A joint statement of 32 European patient organisations, medical associations, research institutes and healthcare companies was published to share their common views on specific recommendations for a potential opt-out mechanism in the EHDS. The group support the approach taken in the Commission's original legislative proposal from May 2022 as it strikes a sensible balance between protection of personal data while enabling the use of data for research and innovation to create tangible benefits for patients and citizens. The stakeholders raise concerns about the real risk that data bias will form part of the EHDS from its inception and thus undermine its principal value for secondary use research purposes if an opt-out or opt-in mechanism is approved, and call for an impact assessment that will inform implementation of this policy option. Click here for the full statement.
Joint Statement: health organisations define EHDS' opt out required for life saving research
On 6 June, OPTIMA joined together with 31 other health stakeholders to share views on specific recommendations for a potential opt-out mechanism in the future EHDS.
These organisations and initiatives have joined forces because they all share the view that health data are precious and renewable resources that can power decision-making for clinical care, deliver life-saving innovations, and strengthen health systems in the 21st century.
Discussions in the EU policy-making process now include proposals for an opt-out mechanism for citizens to withdraw their data from secondary use purposes (that is, from research, regulatory purposes and evidence based policy making). The original European Commission proposal did not include this mechanism.
The group of stakeholders support the approach taken in the Commission's original legislative proposal from May 2022 as it strikes a sensible balance between protection of personal data while enabling the use of data for research and innovation to create tangible benefits for patients and citizens. The stakeholders raise concerns about the real risk that data bias will form part of the EHDS from its inception and thus undermine its principal value for secondary use research purposes if an opt-out or opt-in mechanism is approved, and call for an impact assessment that will inform implementation of this policy option.
If the proposals for opt-out are approved in the final EHDS legislation, the group make six recommendations. They believe the opt-out mechanism should:
- be applicable across all Health Data Access Bodies in EU Member States, limiting the scope of national derogation and ensuring that the technical specifications are aligned.
- consider the impact on health and care professionals and for other data holders.
- be capable of implementation across the EU, without limiting lawful and ethical data sharing for secondary purposes.
- be routinely monitored as part of a regularly updated HealthData@EU data governance framework.
- have a limited, but well-defined, consistent and transparent scope.
- have necessary investment, infrastructure and budget to ensure sufficient transparency so that citizens are well informed of the opt-out.
Finally, the current debate on enabling secondary use of health data in Europe highlights the need to achieve stakeholder alignment where possible on the implementation journey ahead for the EHDS. It also speaks to the need for implementation decisions to be highly informed by those with experience and responsibilities for on-the-ground implementation. This reiterates a need for strong, balanced and inclusive stakeholder representation within the governance model of the EHDS such as its Board of Directors.
Press contact
ARTTIC Innovation GmbH
Karin Rosenits
press@arttic-innovation.de
Project office
European Association of Urology
Emma Jane Smith
ttopstart
Sigrid van Dorp
OPTIMA is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 101034347. IMI2 receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
ARTTIC Innovation GmbH has been advising research and innovation projects for more than 33 years. As project management and communication partner, we make sure that our projects run successfully and that project results and events are disseminated in the best possible way. ARTTIC is a subsidiary of the PNO Group, one of the largest consultancies for publicly funded projects in research and development. For more information, please visit www.arttic-innovation.de.